Research ExplorerPublicationsTherapie der Rezidiv- und Fernmetastasen bei Plattenepithelk...

Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013

Standard

Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013. / Hezel, M; Kurzweg, T; Münscher, A; Schafhausen, P; Knecht, R.

In: HNO, Vol. 61, No. 11, 01.11.2013, p. 911-3.

Research output: SCORING: Contribution to journal › Conference article in journal › Research › peer-review

Harvard

Hezel, M, Kurzweg, T, Münscher, A, Schafhausen, P & Knecht, R 2013, 'Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013', HNO, vol. 61, no. 11, pp. 911-3. https://doi.org/10.1007/s00106-013-2768-2

APA

Hezel, M., Kurzweg, T., Münscher, A., Schafhausen, P., & Knecht, R. (2013). Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013. HNO, 61(11), 911-3. https://doi.org/10.1007/s00106-013-2768-2

Vancouver

Hezel M, Kurzweg T, Münscher A, Schafhausen P, Knecht R. Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013. HNO. 2013 Nov 1;61(11):911-3. https://doi.org/10.1007/s00106-013-2768-2

Bibtex

@article{0faee77b4b8a4c5795aff8aa2902cdcd,
title = "Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013",
abstract = "In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.",
author = "M Hezel and T Kurzweg and A M{\"u}nscher and P Schafhausen and R Knecht",
note = "Leitthema, Zusammenfassung des ASCO 2013, Kongress-Nachschau",
year = "2013",
month = nov,
day = "1",
doi = "10.1007/s00106-013-2768-2",
language = "Deutsch",
volume = "61",
pages = "911--3",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "11",

}

RIS

TY - JOUR

T1 - Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013

AU - Hezel, M

AU - Kurzweg, T

AU - Münscher, A

AU - Schafhausen, P

AU - Knecht, R

N1 - Leitthema, Zusammenfassung des ASCO 2013, Kongress-Nachschau

PY - 2013/11/1

Y1 - 2013/11/1

N2 - In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.

AB - In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.

U2 - 10.1007/s00106-013-2768-2

DO - 10.1007/s00106-013-2768-2

M3 - Konferenzaufsatz in Fachzeitschrift

C2 - 24221219

VL - 61

SP - 911

EP - 913

JO - HNO

JF - HNO

SN - 0017-6192

IS - 11

ER -